ARS Pharmaceuticals, Inc. SPRY Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $98.99M+17.5% | $84.28M-41.0% | $142.77M+27.1% | $112.34M+15.7% | $97.12M+8.9% | ||
| $14.57M+10.5% | $13.18M+3.3% | $12.77M-11.6% | $14.44M-16.5% | $17.3M-11.7% | ||
| $261.22M+13.5% | $230.12M+11.9% | $205.66M+36.9% | $150.19M+43.3% | $104.82M+46.2% | ||
| $301.4M+14.3% | $263.73M+12.9% | $233.56M+36.0% | $171.68M+38.2% | $124.19M+34.6% | ||
| $301.4M+14.3% | $263.73M+12.9% | $233.56M+36.0% | $171.68M+38.2% | $124.19M+34.6% | ||
| -$202.42M-12.8% | -$179.45M— | —— | —— | —— | ||
| -204.5%+8.4pp | -212.9%— | —— | —— | —— | ||
| $4.36M-46.0% | $8.07M-26.9% | $11.03M-5.0% | $11.61M-0.8% | $11.71M+3.0% | ||
| —— | -$171.38M-35.5% | -$126.46M-55.1% | -$81.55M-123% | -$36.63M-542% | ||
| —— | -$80K-767% | $12K-88.5% | $104K-46.9% | $196K-31.9% | ||
| -$197.98M-15.6% | -$171.3M-114% | -$80.04M-66.7% | -$48.02M-207% | -$15.65M-296% | ||
| -200%+3.2pp | -203.3%-147pp | -56.1%-13.3pp | -42.7%-26.6pp | -16.1%-25.1pp | ||
| -$2.01-14.9% | -$1.75-113% | -$0.82-64.0% | -$0.50-194% | -$0.17-343% | ||
| -$2.01-14.9% | -$1.75-113% | -$0.82-64.0% | -$0.50-194% | -$0.17-343% | ||
| 395M+0.3% | 393.8M-1.0% | 397.6M+0.4% | 395.8M+0.4% | 394.3M+0.4% | ||
| 395M+0.3% | 393.8M+0.4% | 392.2M+0.5% | 390.4M+0.4% | 388.9M+0.4% | ||
| $25.62M+25.4% | $20.42M+34.9% | $15.13M+115% | $7.06M+241% | $2.07M+112% | ||
| -$198.14M-15.6% | -$171.39M-113% | -$80.39M-67.8% | -$47.92M-210% | -$15.45M-289% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | $0— | ||
| —— | —— | —— | —— | $11.76M+3.5% | ||
| $4.36M-46.0% | $8.07M-26.9% | $11.03M-5.0% | $11.61M-0.8% | $11.71M+3.0% | ||
| $98.99M+17.5% | $84.28M-41.0% | $142.77M+27.1% | $112.34M+15.7% | $97.12M+8.9% | ||
| -$202.42M-12.8% | -$179.45M-32.0% | -$135.91M-30.1% | -$104.47M-44.7% | -$72.19M-49.8% | ||
| -$200.93M-12.8% | -$178.08M-32.0% | -$134.93M-29.9% | -$103.86M-44.6% | -$71.85M-49.3% | ||
| -$200.93M-12.8% | -$178.08M-32.0% | -$134.93M-29.9% | -$103.86M-44.6% | -$71.85M-49.3% | ||
| -203%+8.3pp | -211.3%-117pp | -94.5%-2.1pp | -92.5%-18.5pp | -74%-20.0pp | ||
| -$202.42M-12.8% | -$179.45M-32.0% | -$135.91M-30.1% | -$104.47M-44.7% | -$72.19M-49.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s revenue?
- ARS Pharmaceuticals, Inc. (SPRY) generated $99.0M in revenue over the trailing twelve months, up 1.9% year over year.
- Is ARS Pharmaceuticals, Inc. profitable?
- ARS Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $198.0M over the trailing twelve months, a -200.0% net margin.
- What is ARS Pharmaceuticals, Inc.'s earnings per share?
- ARS Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-2.01.
- Where does ARS Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from ARS Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
